新诊断的轻链氨基粉症患者的肝脏反应动态:一项回顾性队列研究
Chengyang Xu1, Ai Guan1, Lu Zhang1
1Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 1 Shuaifuyuan, Dongcheng District, Beijing, 100730, People's Republic of China.
Advances in therapy
|January 12, 2026
概括
在AL氨基粉症中,肝脏反应对生存至关重要. 在24个月内达到肝脏器官反应显著改善了预后,早期的血液学反应预测了更好的结果.
科学领域:
- 血液学 血液学 血液学
- 内部医学 内部医学
- 临床研究 临床研究
背景情况:
- 系统性轻链 (AL) 氨基粉症治疗疗效已确定,用于血液学反应.
- 在AL氨基粉症中,肝脏反应模式仍然不太清楚.
- 这项研究侧重于肝损伤患者,他们实现了部分血液反应.
研究的目的:
- 探索AL氨基粉症患者肝脏参与的肝脏反应动态.
- 确定治疗后肝脏反应评估的关键里程碑.
- 为了将肝脏反应与整体存活率和血液反应相关联.
主要方法:
- 使用了两级 (肝脏器官反应/无反应) 和四级 (hepaCR,hepaVGPR,hepaPR,hepaNR) 的肝脏反应标准.
- 在治疗后3,6,12和24个月评估肝脏反应.
- 分析了137名患者的数据,平均随访时间为55.0个月.
主要成果:
- 肝脏器官反应和部分肝脏反应在24个月后停滞不前.
- 在75.6%的患者中,实现了肝脏器官反应.
- 在24个月内实现肝脏器官反应显著改善了预后 (p=0.008).
- 3个月的早期血液完整反应 (CRH) 预测了24个月肝脏器官反应的可能性更高 (OR=2.571).
结论:
- 监测肝脏反应动态在AL氨基粉症治疗中至关重要.
- 3个月的CRH和24个月的肝脏器官反应是治疗的关键里程碑.
- 肝脏反应是AL Amyloidosis的重要预后指标.
相关概念视频
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
176
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
176
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
245
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
245
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
209
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
209
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
206
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
206